Shanghai Fosun Pharmaceutical (02196) subsidiary has initiated Phase I clinical trials for the integrated diagnosis and treatment project SRT-007 in China.
Fosun Pharma announced that its controlled subsidiary, Chengdu Xingrui Jingxuan Biotechnology Co., Ltd., has recently initiated Phase I clinical trials of the integrated diagnosis and treatment core drug project SRT-007 in China (excluding mainland China, Hong Kong, Macau, and Taiwan), with indications for the diagnosis and treatment of metastatic castration-resistant prostate cancer with PSMA-positive.
Shanghai Fosun Pharmaceutical (02196) announced that its holding subsidiary, Chengdu Xingrui Jingxuan Biotechnology Co., Ltd., has recently initiated Phase I clinical trials for the integrated diagnosis and treatment nuclear medicine project SRT-007 in China (excluding Hong Kong, Macao, and Taiwan). The indication is for the diagnosis and treatment of metastatic castration-resistant prostate cancer with PSMA-positive.
Related Articles
TIANJIN CAPITAL (01065): Elect Fu Xinghai as employee director.
GOLDEN FAITH GP(02863) announces annual performance, with a net loss attributable to owners of the company of 17.938 million Hong Kong dollars, an increase of 184.14% year-on-year.
BeautyFarm MED (02373) subscribed to a guaranteed capital preservation wealth management product worth 80 million yuan.
TIANJIN CAPITAL (01065): Elect Fu Xinghai as employee director.
GOLDEN FAITH GP(02863) announces annual performance, with a net loss attributable to owners of the company of 17.938 million Hong Kong dollars, an increase of 184.14% year-on-year.
BeautyFarm MED (02373) subscribed to a guaranteed capital preservation wealth management product worth 80 million yuan.
